Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic spontaneous urticaria
Pharma
Novartis' BTK inhibitor wins FDA approval in chronic hives
Novartis' Rhapsido has become the first oral BTK inhibitor approved for chronic spontaneous urticaria.
Angus Liuu
Sep 30, 2025 6:40pm
FDA approves Sanofi, Regeneron’s Dupixent for hives disorder
Apr 18, 2025 11:47am
Sanofi, Regeneron to seek FDA nod for Dupixent in hives disorder
Sep 11, 2024 1:00am
After FDA says no on Dupixent for hives disorder, Japan says yes
Feb 16, 2024 10:54am
FDA rejects Sanofi, Regeneron's Dupixent to treat hives disorder
Oct 23, 2023 10:38am
Novartis targets new fields—and CAR-T—for immunology growth
May 10, 2023 5:00pm
